ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average […]

Leave a Reply

Your email address will not be published.

Previous post Head-To-Head Analysis: Dream Finders Homes (NYSE:DFH) vs. Green Brick Partners (NASDAQ:GRBK)
Next post Ingredion Incorporated (NYSE:INGR) Given Consensus Rating of “Hold” by Analysts